FDA Approves Alcon’s BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking Eyes

Alcon's Brytly (apraclonidine 0.125%) received FDA approval for OTC red-eye relief. It will be available online and at major retailers soon. The drug shows effects in one minute, lasting up to 12 hours, and is approved for adults and children 12+.

Alcon (ALC, ALC.SW) received FDA approval for BRYTLY Redness Reliever Eye Drops, an OTC treatment for eye redness. The product starts working in one minute and lasts up to 12 hours. Alcon claims it lasts 50% longer than Lumify and is safe and effective. The company expects to launch BRYTLY at major retailers and online soon. ALC closed at $66.18 on Friday, down 0.60%.

Alcon (ALC) received FDA approval for Brytly, an OTC eye drop. The company claims it provides 12-hour redness relief, lasting 50% longer than Bausch + Lomb's (BLCO) Lumify. Studies suggest low risk of redness rebound and tachyphylaxis.

Alcon's BRYTLY Redness Reliever Eye Drops received FDA approval, reducing redness in a minute and lasting up to 12 hours. The product will expand Alcon's consumer eye care portfolio and be available nationwide. According to Alcon, BRYTLY is clinically proven to be safe and effective, with low risk of rebound redness.

Barclays initiated coverage on 26 medical device makers, rating Stryker (SYK) and Abbott Laboratories (ABT) as Overweight. Analyst Christopher Pasquale cited compelling valuations and a potential stabilization of revenue as catalysts. Price targets were set for several companies, including SYK at $375 and ABT at $120.

Bernstein recommends Sonova (CHF 275 PT) and Alcon (CHF 76.15 PT) as top European medtech picks for H2, citing strong growth prospects and attractive valuations. Sonova is favored for short-term gains, while Alcon is seen as a long-term compounder. Bernstein's estimates for both companies are above consensus.